NASDAQ:SCNX Scienture (SCNX) Stock Price, News & Analysis $0.40 +0.01 (+3.71%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Scienture Stock (NASDAQ:SCNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Scienture alerts:Sign Up Key Stats Today's Range$0.38▼$0.4150-Day Range$0.33▼$0.4252-Week Range$0.24▼$2.60Volume205,041 shsAverage Volume2.25 million shsMarket Capitalization$16.37 millionP/E RatioN/ADividend YieldN/APrice Target$1.50Consensus RatingHold Company Overview Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL. Read More Scienture Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreSCNX MarketRank™: Scienture scored higher than 51% of companies evaluated by MarketBeat, and ranked 939th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingScienture has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialScienture has a consensus price target of $1.50, representing about 286.0% upside from its current price of $0.39.Amount of Analyst CoverageScienture has only been the subject of 1 research reports in the past 90 days.Read more about Scienture's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Scienture is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scienture is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScienture has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Scienture's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.93% of the float of Scienture has been sold short.Short Interest Ratio / Days to CoverScienture has a short interest ratio ("days to cover") of 3.22, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scienture has recently decreased by 20.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScienture does not currently pay a dividend.Dividend GrowthScienture does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Scienture this week, compared to 2 articles on an average week.Search Interest2 people have searched for SCNX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Scienture to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scienture insiders have not sold or bought any company stock.Percentage Held by Insiders21.39% of the stock of Scienture is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.68% of the stock of Scienture is held by institutions.Read more about Scienture's insider trading history. Receive SCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scienture and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCNX Stock News HeadlinesScienture (NASDAQ:SCNX) Trading Down 6.6% - Time to Sell?July 22 at 2:20 AM | americanbankingnews.comScienture Holdings stock jumps over 20% pre-market: Here's whyJuly 10, 2026 | msn.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.July 22 at 1:00 AM | Porter & Company (Ad)SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to WholesalersJuly 9, 2026 | finance.yahoo.comSCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to WholesalersJuly 9, 2026 | globenewswire.comSCNX Share News TodayJuly 4, 2026 | uk.investing.comScienture Holdings (SCNX) Stock Forecast & Price TargetJune 25, 2026 | investing.comScienture Holdings Stock Short Interest Report | NASDAQ:SCNX | BenzingaJune 24, 2026 | benzinga.comSee More Headlines SCNX Stock Analysis - Frequently Asked Questions How have SCNX shares performed this year? Scienture's stock was trading at $0.51 at the beginning of the year. Since then, SCNX shares have decreased by 23.8% and is now trading at $0.3886. How were Scienture's earnings last quarter? Scienture Holdings, Inc. (NASDAQ:SCNX) issued its quarterly earnings data on Friday, May, 15th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.15. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.40 million. How do I buy shares of Scienture? Shares of SCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scienture own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scienture investors own include Cogent Communications (CCOI), Cavco Industries (CVCO), Liberty Broadband (LBRDK), Liberty Global (LBTYB), PayPal (PYPL), Roku (ROKU) and Arch Capital Group (ACGL). Company Calendar Last Earnings5/15/2026Today7/22/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 SCNX's financial health is in the Yellow zone, according to TradeSmith. SCNX has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryWholesale Current SymbolNASDAQ:SCNX Previous SymbolNASDAQ:MEDS CIK1382574 Webwww.trxadehealth.com Phone(800) 261-0281Fax800-265-6932EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Scienture$1.50 High Price Target$1.50 Low Price Target$1.50 Potential Upside/Downside+273.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.51 million Net MarginsN/A Pretax Margin-9,191.82% Return on Equity-56.28% Return on Assets-44.76% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.63 Sales & Book Value Annual Sales$430 thousand Price / Sales37.98 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book0.23Miscellaneous Outstanding Shares40,630,000Free Float31,940,000Market Cap$16.33 million OptionableN/A Beta3.28 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SCNX) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe smarter SpaceX play most investors will missOn July 1st, a brand-new blockchain went live. Traders flooded in. Memecoins launched by the hour. And accordi...Crypto 101 Media | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredNNVC: FDA = New Momentum Wave!NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...Equiscreen | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredYour First Trade Playbook is expiringMost beginners stay stuck on the sidelines for years because no one shows them the simple steps between being ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scienture Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scienture With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
